Dian Bolhuis presented promising results from the first-in-human clinical trial of the portable Wearable Artificial Kidney (WEAKID) at the International Society for Peritoneal Dialysis (ISPD) Congress 2026, held in Cape Town, South Africa, from 29 September to 3 October. The findings represent an important step towards more efficient and flexible peritoneal dialysis treatment.

Advancing peritoneal dialysis technology
The WEAKID device is an innovative, portable system designed to improve peritoneal dialysis (PD) treatment. Unlike conventional PD systems, which use periods of stationary dialysis fluid in the abdomen, WEAKID creates a continuous flow of dialysate and uses sorbent technology to regenerate the dialysis fluid.
This innovative approach aims to improve the removal of waste products and excess fluid while potentially offering patients greater freedom of movement. Weighing approximately 4.5 kg without dialysate, the portable device could ultimately contribute to improved mobility and quality of life for people dependent on dialysis.
Encouraging clinical results
During her presentation, titled “The portable WEarable Artificial KIDney (WEAKID) device for peritoneal dialysis: Preliminary safety and efficacy results from the First-in-Human trial,” Dian Bolhuis shared findings from a clinical study conducted between January 2024 and December 2025.
The international study involved three clinical centres in the Netherlands, Spain, and Italy. Of the 13 patients enrolled, 12 received WEAKID treatment, completing a total of 66 treatment sessions.
The preliminary findings were encouraging. Continuous dialysate flow was well tolerated, and no critical changes in vital signs or laboratory parameters were observed. One serious device-related adverse effect involving mechanical peritonitis was reported, likely associated with a use error.
Importantly, the study also demonstrated the potential of WEAKID to improve dialysis efficiency. Compared with conventional automated peritoneal dialysis (APD), eight-hour WEAKID treatments using sorbents showed increased plasma clearance for several substances:
- 19% higher creatinine clearance
- 15% higher phosphate clearance
- 4% higher potassium clearance
These preliminary results suggest that continuous dialysate flow combined with sorbent-based regeneration could enhance the effectiveness of peritoneal dialysis.

Building on the results
The findings provide a valuable foundation for the next phase of WEAKID development. Based on insights gained during the trial, the device is currently being redesigned to further optimize treatment efficiency, particularly by reducing dialysate recirculation and dead volume.
A larger clinical trial is planned to further evaluate the safety and effectiveness of the redesigned system.
Although additional research is needed before WEAKID can become an established treatment option, these first-in-human results mark an encouraging milestone in the development of portable dialysis technology.

International collaboration
The WEAKID first-in-human trial was made possible through close collaboration between University Medical Center Utrecht (the Netherlands), University Hospital La Paz (Spain), the University of Modena and Reggio Emilia (Italy), and Nanodialysis B.V. (the Netherlands).
Presenting these findings at ISPD 2026 provided an important opportunity to share the progress of WEAKID with the international peritoneal dialysis community and contribute to ongoing innovation in kidney care.
Read more: ISPD 2026 Scientific Programme, Home – Project Cordial
